 ROCHESTER, N.Y., Jan. 05, 2021 GLOBE NEWSWIRE -- Vaccinex, Inc. Nasdaq: VCNX, a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021. 